The market demand drives the sales growth, and these varieties have performed well in recent years

[product information of pharmaceutical Station] with the growth of the demand of the pharmaceutical market, a batch of drugs also ushered in a period of sales growth, including new drugs, generic drugs and imported drugs Based on the hospital drug sales, from 2012 to 108, there were several types of drugs increasing in the domestic sales of billion yuan drugs Specifically, it includes ateplase, idebenone, budesonide, butylphthalide, febutasta, bortezomib, mycophenolate sodium, loplatin, leuprorelin, letetrexed, Avastin, etc From 2012 to 2018, the sales amount of ateplase increased year by year, from 147 million in 2012 to 636 million yuan Ateplase is a thrombolytic agent, mainly composed of glycoprotein, containing 526 amino acids Ateplase can bind to fibrin through its lysine residue, and activate plasminogen bound to fibrin to change into plasminogen, which is significantly stronger than plasminogen in the activation cycle of this drug After intravenous injection, the drug reaches the thrombus site through blood circulation After combining with thrombus, it can quickly dissolve the thrombus, reopen the blocked blood vessels, save the ischemic brain cells and tissues, so as to improve the symptoms of Limb asthenia and unclear speech Budesonide is a light beige solid chemical with local anti-inflammatory effect of glucocorticoids, which can enhance the stability of endothelial cells, smooth muscle cells and lysosomal membranes, inhibit immune response and reduce antibody synthesis It is clinically used in patients with glucocorticoid dependent or non dependent asthma and asthmatic chronic bronchitis The sales market of budesonide in the hospital gradually increased from 1471 million yuan in 2012 to 3889 million yuan The author understands that the sales and market share of budesonide's chemical antiasthmatic drugs in urban public hospitals from 2013 to 2015 are increasing year by year In 2015, the sales are 3349.72 million yuan, accounting for 28.06% of the market share It can be seen that budesonide's market share in antiasthmatic drugs is relatively large Non bustard and non bustard are suitable for the long-term treatment of hyperuricemia with gout symptoms From 2014 to 2018, the sales volume of non bustard also showed a rising trend, from 18 million to 704 million, with an alarming increase It is understood that the synthesis and metabolism of other purines and pyrimidines will not be affected under the concentration of non bustatin conventional treatment, and the low dose can play a higher activity, which is relatively safe For patients who are not suitable for allopurinol treatment, the curative effect is accurate and the safety tolerance is good Avastin is a kind of competitive histamine H1 receptor antagonist with moderate intensity, which belongs to histamine From 2012 to 2018, the sales volume of Avastin increased from RMB 01 million to RMB 20 million Avastin is a phenazine antihistamine antiallergic drug launched by Glaxo Wellcome in the late 1980s Avastin can inhibit the expansion and increase of capillary permeability, reduce vascular exudation, inhibit the spasm of respiratory tract and digestive tract smooth muscle In recent years, Avastin has been found to have the protective effect of mast cell membrane, and is not easy to penetrate blood and brain A barrier.